» Authors » Ka Hyun Paek

Ka Hyun Paek

Explore the profile of Ka Hyun Paek including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 238
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakamoto A, Kawakami R, Mori M, Guo L, Paek K, Mosquera J, et al.
JCI Insight . 2023 Jan; 8(5). PMID: 36719758
Vascular calcification (VC) is concomitant with atherosclerosis, yet it remains uncertain why rupture-prone high-risk plaques do not typically show extensive calcification. Intraplaque hemorrhage (IPH) deposits erythrocyte-derived cholesterol, enlarging the necrotic...
2.
Cornelissen A, Guo L, Fernandez R, Kelly M, Janifer C, Kuntz S, et al.
Arterioscler Thromb Vasc Biol . 2021 Jun; 41(8):2277-2292. PMID: 34162228
OBJECTIVE: Healing processes, particularly reendothelialization, are essential for vascular homeostasis after plain old balloon angioplasty and stent implantation. Drug-eluting stents (DES) are commonly used for percutaneous coronary intervention because restenosis...
3.
Cornelissen A, Fuller D, Fernandez R, Zhao X, Kutys R, Binns-Roemer E, et al.
Arterioscler Thromb Vasc Biol . 2021 May; 41(7):2201-2214. PMID: 34039022
[Figure: see text].
4.
Sakamoto A, Torii S, Jinnouchi H, Fuller D, Cornelissen A, Sato Y, et al.
J Vasc Interv Radiol . 2021 Mar; 32(6):792-801.e5. PMID: 33677117
Purpose: To compare the long-term vascular healing responses of healthy swine iliofemoral arteries treated with a polymer-free paclitaxel-eluting stent (Z-PES, Zilver PTX) or a fluoropolymer-based paclitaxel-eluting stent (FP-PES, Eluvia). Materials...
5.
Sakamoto A, Torii S, Jinnouchi H, Guo L, Cornelissen A, Kuntz S, et al.
Cardiovasc Revasc Med . 2020 Sep; 24:1-10. PMID: 32928693
Aims: The advantage of biodegradable-polymer drug-eluting stents (BP-DES) versus durable-polymer (DP) DES remains uncertain. We compared neointimal formation and endothelial barrier function of new BP sirolimus-eluting stents (BP-SES, BuMA Supreme®)...
6.
Jinnouchi H, Guo L, Sakamoto A, Sato Y, Cornelissen A, Kawakami R, et al.
Future Med Chem . 2020 May; 12(12):1181-1195. PMID: 32431177
Mammalian target of rapamycin (mTOR) inhibitors have been applied to vascular coronary devices to avoid neointimal growth and have become the predominant pharmacological agents used to prevent restenosis. mTOR inhibitors...
7.
Jinnouchi H, Sato Y, Torii S, Sakamoto A, Cornelissen A, Bhoite R, et al.
EuroIntervention . 2020 Apr; 16(5):395-403. PMID: 32310132
Aims: The aim of this study was to determine the ability of optical frequency domain imaging (OFDI)/optical coherence tomography (OCT) imaging systems to visualise the presence of cholesterol crystals (CCR)...
8.
Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa F, et al.
Eur Heart J . 2019 Dec; 41(6):786-796. PMID: 31803916
Aims: Vascular calcification is routinely encountered in percutaneous coronary intervention (PCI) and severe coronary calcification is a known predictor of in-stent restenosis and stent thrombosis. However, the histopathologic mechanisms behind...
9.
Jinnouchi H, Guo L, Sakamoto A, Torii S, Sato Y, Cornelissen A, et al.
Cell Mol Life Sci . 2019 Nov; 77(10):1919-1932. PMID: 31720740
The presence of macrophages within the plaque is a defining hallmark of atherosclerosis. Macrophages are exposed to various microenvironments such as oxidized lipids and cytokines which effect their phenotypic differentiation...
10.
Torii S, Jinnouchi H, Sakamoto A, Kutyna M, Cornelissen A, Kuntz S, et al.
Nat Rev Cardiol . 2019 Jul; 17(1):37-51. PMID: 31346257
Implantation of drug-eluting stents (DES) is the dominant treatment strategy for patients with symptomatic coronary artery disease. However, the first-generation DES had substantial drawbacks, including delayed healing, local hypersensitivity reactions...